Connect with us

AI Insights

Global Artificial Intelligence (AI) in Clinical Trials Market

Published

2 months ago

on


According to DelveInsight’s analysis, The demand for Artificial Intelligence in clinical trials is experiencing strong growth, primarily driven by the rising global prevalence of chronic conditions like diabetes, cardiovascular diseases, respiratory illnesses, and cancer. This growth is further supported by increased investments and funding dedicated to advancing drug discovery and development efforts. Additionally, the growing number of strategic collaborations and partnerships among pharmaceutical, biotechnology, and medical device companies is significantly boosting the adoption of AI-driven solutions in clinical trials. Together, these factors are anticipated to fuel the expansion of the AI in the clinical trials market during the forecast period from 2025 to 2032.

DelveInsight’s “Artificial Intelligence (AI) in Clinical Trials Market Insights, Competitive Landscape and Market Forecast-2032” report provides the current and forecast market outlook, forthcoming device innovation, challenges, market drivers and barriers. The report also covers the major emerging products and key Artificial Intelligence (AI) in Clinical Trials companies actively working in the market.

To know more about why North America is leading the market growth in the Artificial Intelligence (AI) in Clinical Trials market, get a snapshot of the report Artificial Intelligence (AI) in Clinical Trials Market Trends

https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Artificial Intelligence (AI) in Clinical Trials Overview

Artificial Intelligence (AI) in clinical trials refers to the use of advanced machine learning algorithms and data analytics to streamline and improve various aspects of clinical research. AI enhances trial design, patient recruitment, site selection, and data analysis by identifying patterns and predicting outcomes. It enables faster patient matching, optimizes protocol design, reduces trial timelines, and improves data quality and monitoring. AI also helps in real-time adverse event detection and adaptive trial management, making clinical trials more efficient, cost-effective, and patient-centric.

DelveInsight Analysis: The global Artificial Intelligence in clinical trials market size was valued at USD 1,350.79 million in 2024 and is projected to expand at a CAGR of 12.04% during 2025-2032, reaching approximately USD 3,334.47 million by 2032.

Artificial Intelligence (AI) in Clinical Trials Market Insights

Geographically, North America is expected to lead the AI in the clinical trial market in 2024, driven by several critical factors. The region’s growing burden of chronic diseases, substantial investments in R&D, and the rising volume of clinical trials contribute significantly to this dominance. Additionally, an increasing number of collaborations and partnerships among pharmaceutical and medical device companies, along with the advancement of sophisticated AI solutions, are accelerating market expansion. These developments are enhancing the ability to manage complex clinical trials efficiently, driving the adoption of AI technologies and supporting the market’s growth in North America throughout the forecast period from 2025 to 2032.

To read more about the latest highlights related to Artificial Intelligence (AI) in Clinical Trials, get a snapshot of the key highlights entailed in the Artificial Intelligence (AI) in Clinical Trials

https://www.delveinsight.com/report-store/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Recent Developments in the Artificial Intelligence (AI) in Clinical Trials Market Report

• In May 2025, Avant Technologies, Inc. (OTCQB: AVAI) and joint venture partner Ainnova Tech, Inc. announced the initiation of acquisition discussions aimed at enhancing their presence in the rapidly growing AI-powered healthcare sector.

• In March 2025, Suvoda introduced Sofia, an AI-driven assistant created to optimize clinical trial management processes. Sofia aids study teams by providing quick access to essential trial data and real-time, intelligent insights. This tool boosts operational efficiency, minimizes manual tasks, and helps teams make faster, data-informed decisions throughout the clinical trial journey.

• In December 2024, ConcertAI and NeoGenomics unveiled CTO-H, an advanced AI-powered software platform designed to enhance research analytics, clinical trial design, and operational efficiency. CTO-H provides an extensive research data ecosystem, offering comprehensive longitudinal patient data, deep biomarker insights, and scalable analytics to support more precise, efficient, and data-driven clinical development processes.

• In June 2024, Lokavant introduced SpectrumTM, the first AI-powered clinical trial feasibility solution aimed at enhancing trial performance throughout the clinical development process. Spectrum enables study teams to forecast, control, and improve trial timelines and expenses in real-time.

• Thus, owing to such developments in the market, rapid growth will be observed in the Artificial Intelligence (AI) in Clinical Trials market during the forecast period

Key Players in the Artificial Intelligence (AI) in Clinical Trials Market

Some of the key market players operating in the Artificial Intelligence (AI) in Clinical Trials market include- TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and others.

Which MedTech key players in the Artificial Intelligence (AI) in Clinical Trials market are set to emerge as the trendsetter explore @ Key Artificial Intelligence (AI) in Clinical Trials Companies

https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Analysis on the Artificial Intelligence (AI) in Clinical Trials Market Landscape

To meet the growing needs of clinical trials, leading companies in the AI in Clinical Trials market are creating advanced AI solutions aimed at improving trial efficiency, optimizing patient recruitment, and enhancing clinical trial design at investigator sites. For example, in April 2023, ConcertAI introduced CTO 2.0, a clinical trial optimization platform that utilizes publicly available data and partner insights to deliver comprehensive site and physician-level trial data. This tool provides key operational metrics and site profiles to evaluate trial performance and site capabilities. Additionally, CTO 2.0 assists sponsors in complying with FDA requirements for inclusive trial outcomes, promoting a shift toward community-based trials with more streamlined and patient-centric designs.

As a result of these advancements, the software segment is projected to experience significant growth throughout the forecast period, contributing to the overall expansion of the AI in the clinical trials market.

Scope of the Artificial Intelligence (AI) in Clinical Trials Market Report

• Coverage: Global

• Study Period: 2022-2032

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Product Type: Software and Services

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Technology Type: Machine Learning (ML), Natural Language Processing (NLP), and Others

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Application Type: Clinical Trial Design & Optimization, Patient Identification & Recruitment, Site Identification & Trial Monitoring, and Others

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By End-User: Pharmaceutical & Biotechnology Companies and Medical Device Companies

• Artificial Intelligence (AI) in Clinical Trials Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World

• Key Artificial Intelligence (AI) in Clinical Trials Companies: TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, and others

• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Interested in knowing how the Artificial Intelligence (AI) in Clinical Trials market will grow by 2032? Click to get a snapshot of the Artificial Intelligence (AI) in Clinical Trials Market Analysis

https://www.delveinsight.com/sample-request/ai-in-clinical-trials-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents

1 Artificial Intelligence (AI) in Clinical Trials Market Report Introduction

2 Artificial Intelligence (AI) in Clinical Trials Market Executive summary

3 Regulatory and Patent Analysis

4 Artificial Intelligence (AI) in Clinical Trials Market Key Factors Analysis

5 Porter’s Five Forces Analysis

6 COVID-19 Impact Analysis on Artificial Intelligence (AI) in Clinical Trials Market

7 Artificial Intelligence (AI) in Clinical Trials Market Layout

8 Global Company Share Analysis – Key Artificial Intelligence (AI) in Clinical Trials Companies

9 Company and Product Profiles

10 Project Approach

11 Artificial Intelligence (AI) in Clinical Trials Market Drivers

12 Artificial Intelligence (AI) in Clinical Trials Market Barriers

13 About DelveInsight

Latest Reports by DelveInsight

• Percutaneous Arterial Closure Device Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market

• Transdermal Drug Delivery Devices: https://www.delveinsight.com/report-store/transdermal-drug-delivery-devices-market

• Infusion Pumps Market: https://www.delveinsight.com/report-store/infusion-pumps-market

• Acute Radiation Syndrome Market: https://www.delveinsight.com/report-store/acute-radiation-syndrome-pipeline-insight

• Human Papillomavirus Hpv Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market

• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market

Contact Us

Gaurav Bora

info@delveinsight.com

+14699457679

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.



Source link

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

AI Insights

2 Popular AI Stocks to Sell Before They Fall 46% and 73%, According to Wall Street Analysts

Published

56 minutes ago

on

September 14, 2025

By


Popular artificial intelligence (AI) stocks Palantir and Arm may be headed for colossal losses.

Shares of Palantir Technologies (PLTR 4.14%) have returned 2,570% since the artificial intelligence (AI) boom began in earnest in January 2023. Arm Holdings (ARM -2.62%) did not go public until September 2023, but shares have since advanced 195%. Those gains have left both stocks trading at rich valuations, so much so that certain Wall Street analysts recommend selling.

  • Rishi Jaluria at RBC Capital has set a target price of $45 per share for Palantir. That implies 73% downside from its current share price of $171.
  • Javier Correonero at Morningstar has set a target price of $80 per share for Arm. That implies 46% downside from its current share price of $150.

Here’s what investors should know about these popular AI stocks.

Image source: Getty Images.

Palantir Technologies: 73% implied downside

Palantir introduced its Artificial Intelligence Platform (AIP) in April 2023. It serves as a large language model organization tool that complements its core data analytics platforms by letting developers integrate generative AI into applications and workflows. The product has been an unmitigated success, such that sales growth has accelerated in eight consecutive quarters.

Palantir’s advantage lies in its unique ontology-based software architecture. In this context, an ontology is a framework that integrates an organization’s data, assets, and actions into a digital twin that supports decision-making. It also captures the outcome of every decision and feeds the information back into the models, which creates a feedback loop that leads to better insights over time.

International Data Corp. ranked Palantir as the market leader in decision intelligence platforms last year. That bodes well for the company. Grand View Research estimates that data analytics software sales will increase at 29% annually through 2030. “The main factors propelling the data analytics industry expansion are the growing adoption of machine learning and artificial intelligence,” according to the report.

However, Palantir is one of the most richly valued software stocks in history. It currently trades at 126 times sales, which makes it the most expensive stock in the S&P 500 by a long shot. The second-most expensive stock is Texas Pacific Land at 29 times sales. That means Palantir would still be the most expensive stock in the index even if it lost 75% of its value.

In that context, it is entirely plausible that Palantir will suffer a major meltdown at some point in the future. Prospective investors should avoid the stock or, at the very least, keep any positions very small. Current shareholders with a substantial percentage of their portfolios invested in Palantir should consider trimming their positions.

Arm Holdings: 46% implied downside

Arm has long dominated the market for mobile device processors due to its power-efficient architecture. Its central processing units (CPUs) are found in 99% of smartphones. But that quality, coupled with the flexibility of its licensing model — Arm does not make chips, but rather licenses blueprints to customers who develop custom chips — has also helped it gain market share in data centers.

Major technology companies, such as Alphabet, Amazon, Apple, and Microsoft, have designed Arm-based server processors. And Nvidia‘s Grace Blackwell Superchip pairs two Blackwell GPUs with an Arm-based Grace CPU. In total, Arm has added about 10 percentage points of market share in data centers in the last two years, while Intel has lost about 16 points. AMD has also gained share, which accounts for the difference.

That trend is likely to continue as companies look to curb operating costs associated with AI infrastructure by deploying more power-efficient server processors. CEO Rene Hass recently said AI is “driving unprecedented demand for compute that’s not only performant, but also energy efficient. And Arm is the only compute platform built to deliver.”

However, Arm currently trades at 94 times adjusted earnings. That is particularly expensive for a company whose earnings are forecasted to increase at 23% annually through fiscal 2027. Those figures give Arm a price/earnings-to-growth (PEG) ratio above 4, which is traditionally seen as overvalued. Moreover, Arm trades at 39 times sales, which makes it the third-most expensive stock in the Nasdaq-100, behind Palantir and Strategy.

I doubt Arm shares will decline 46% unless the broader market drops sharply, but the stock is very expensive. Investors should wait for a better entry point before putting money into this semiconductor company. Personally, I would feel more comfortable buying at $120 per share, though the valuation would still be stretched even at that price.

Trevor Jennewine has positions in Amazon, Nvidia, and Palantir Technologies. The Motley Fool has positions in and recommends Advanced Micro Devices, Alphabet, Amazon, Apple, Intel, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft, short January 2026 $405 calls on Microsoft, and short November 2025 $21 puts on Intel. The Motley Fool has a disclosure policy.



Source link

Continue Reading

AI Insights

2 Artificial Intelligence (AI) Stocks to Buy Before They Soar to $5 Trillion, According to a Wall Street Expert

Published

1 hour ago

on

September 14, 2025

By


Philippe Laffont, one of Wall Street’s most successful hedge fund managers, expects Microsoft and Nvidia to be the most valuable companies in the world by 2030.

Billionaire Philippe Laffont runs Coatue Management, a successful hedge fund that nearly tripled the returns in the S&P 500 over the last three years. Coatue curates the Fantastic 40 Growth & Innovation Index, which distills the 150 largest technology companies into a list of 40 stocks best positioned to lead the market in the years ahead.

Microsoft (MSFT 1.82%) and Nvidia (NVDA 0.43%) currently top that list. Coatue expects them to be the largest companies in the world by 2030, with market values approaching $6 trillion, as detailed below:

  • Coatue estimates Microsoft will be worth $5.7 trillion in 2030. That implies 54% upside from its current market value of $3.7 trillion.
  • Coatue estimates Nvidia will be worth $5.6 trillion in 2030. That implies 30% upside from its current market value of $4.3 trillion.

Importantly, Laffont has put his money where his mouth is. Microsoft and Nvidia are two of the largest positions in his $36 billion portfolio, accounting for over 10% of his invested assets. Here’s what investors should know about these artificial intelligence stocks.

Image source: Getty Images.

1. Microsoft

Microsoft is the largest enterprise software company and the second-largest public cloud provider, and it’s using its strength in those markets to profit from artificial intelligence (AI). Its family of Copilot applications, which automate work across software such as Microsoft 365 and Dynamics 365, surpassed 100 million monthly active users in the most recent quarter.

CEO Satya Nadella says customers are adopting Microsoft 365 Copilot faster than any other product in the business productivity suite. And traction with Copilot is driving the adoption of Copilot Studio, which lets users build AI agents using company-specific data by simply describing the desired functionality in natural language.

In cloud computing, Microsoft recently introduced Azure AI Foundry, a suite of pretrained models and tools that let customers develop, customize, and manage AI applications. “All up, 80% of Fortune 500 companies already use Foundry,” according to Satya Nadella. “We continue to lead the AI infrastructure wave and took share every quarter this year.”

Microsoft reported encouraging fourth-quarter financial results in fiscal 2025, which ended in June. Revenue increased 18% to $76 billion, driven by particularly strong growth in cloud services, where revenue accelerated for the second straight quarter. Commercial bookings growth also accelerated to 37%, hinting at strong future sales growth. And GAAP (generally accepted accounting principles) earnings rose 24% to $3.65 per diluted share.

Wall Street expects Microsoft’s earnings to increase at 12% annually during the next three years. That makes the current valuation of 37 times earnings look expensive, but analysts may be underestimating it. Enterprise software and cloud services spending through 2030 are likely to grow at 12% annually and 20% annually, respectively, according to Grand View Research.

That gives Microsoft a good shot at annual earnings growth in the mid-teens, which makes the stock look a little more attractive and could carry the company to a $5 trillion market value by 2030. Nevertheless, it makes sense to start with a very small position due to the elevated valuation. You can always buy more shares if the stock pulls back.

2. Nvidia

Nvidia dominates the market for data center graphics processing units (GPUs), chips that function as accelerators for demanding workloads such as AI training and inference. The company currently holds more than 80% market share in AI accelerators, and Morgan Stanley analysts think Nvidia will maintain that same level of dominance for years to come, despite intense competition.

Several large customers — Microsoft, Amazon, and Alphabet — have developed custom AI accelerators, called application-specific integrated circuits (ASICs), but they are unlikely to dethrone Nvidia GPUs because they lack ready-made software development tools. In other words, custom chips need custom software tools, and designing those products requires a great deal of technical expertise that most companies lack.

Nvidia introduced its CUDA software platform nearly two decades ago, and it has become an unparalleled ecosystem of code libraries, pretrained models, and frameworks that help developers build applications across use cases such as content generation, computer vision, predictive analytics, and autonomous machines. I/O Fund analyst Beth Kindig says CUDA affords Nvidia an “impenetrable moat.”

Wall Street expects Nvidia’s earnings to increase at 36% annually over the next three years, a sensible estimate, given that AI accelerator sales are forecasted to increase at 36% annually through 2030. That makes Nvidia’s current valuation of 51 times earnings look reasonable. I have no doubt that Nvidia is on its way to a $5 trillion valuation, and I expect the company to hit that milestone well before 2030.

Trevor Jennewine has positions in Amazon and Nvidia. The Motley Fool has positions in and recommends Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.



Source link

Continue Reading

AI Insights

The battle for artificial intelligence (AI) talents triggered in Silicon Valley is spreading to Chin..

Published

2 hours ago

on

September 14, 2025

By


Tsinghua University and Princeton University, Yao Ranked OpenAI Leave and Join Tencent

Tencent Logo

The battle for artificial intelligence (AI) talents triggered in Silicon Valley is spreading to China.

Bloomberg News reported on the 13th (local time) that Tencent recruited Yao Sun-ji, a researcher from OpenAI. Tencent reportedly joined Yao to take on the task of integrating AI throughout its services and offered a compensation package worth up to 100 million yuan (about 20 billion won).

Yao graduated from Tsinghua University in China and obtained a Ph.D. in computer science from Princeton University in the United States. Since then, he has worked as a Google intern and continued his research activities at OpenAI since June last year. He has recently led research on ‘language-based agents’, one of the most high-profile topics in the field of AI.

In particular, Yao has been recognized in the industry as much as Mark Zuckerberg, CEO of Meta, pushed for recruitment while setting up a team dedicated to super-intelligence.

The battle for AI talent is spreading beyond just competition at the corporate level to the national strategic level. China is actively encouraging overseas researchers to return as well as developing its own chips as the U.S. regulations on the export of Nvidia AI chips have disrupted its development. According to Nature, the Chinese government and large companies such as Baidu and Tencent have recently set out unconventional conditions for returning workers, such as supporting family migration, providing housing, and sponsoring research funds. [Silicon Valley correspondent Wonho-seop]



Source link

Continue Reading

Trending